AlphaStocks
3.2
Weak

DANAHER CORP /DE/ (DHR)

Health Care / Life Sciences Tools & Services

S&P 500

$195.01

Scores poorly across most models. Proceed with caution.

Weak

Score based on 5 of 5 models — high confidence

#959out of 1123 in Health Care

Is DANAHER CORP /DE/ a Good Investment in 2026?

DANAHER CORP /DE/ (DHR) scores 3.2 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates DANAHER CORP /DE/ as Attractive (5/9). The Greenblatt Magic Formula model is the least favorable, rating it Neutral. DANAHER CORP /DE/ currently trades above its estimated fair value of $140, suggesting limited upside at current prices. DANAHER CORP /DE/ ranks #959 out of 1123 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E38.6ROE7.0Market Cap139BDiv Yield0.6

Estimated Fair Value

$139.6740% above

Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of -5% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Neutral

Top half (rank 26%)

Frequently Asked Questions

Is DANAHER CORP /DE/ (DHR) a good investment?
Based on AlphaStocks' composite analysis, DANAHER CORP /DE/ (DHR) scores 3.2 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of -5% may not justify the premium.
What is DANAHER CORP /DE/'s Piotroski F-Score?
DANAHER CORP /DE/'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is DHR overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $140, DHR appears overvalued. The stock currently trades 40% above its estimated fair value. Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of -5% may not justify the premium.
How does DHR compare to other Health Care stocks?
DANAHER CORP /DE/ ranks #959 out of 1123 stocks in the Health Care sector, placing it in the top 85% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about DHR?
AlphaStocks evaluates DHR using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 3.2/10.

Similar Stocks

PARRBFAMNTAP

Compare DHR with

DHR vs PARRDHR vs BFAMDHR vs NTAP

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer